CorMatrix(R) ECM(TM) Receives CE Mark for Cardiac Tissue Repair

Product Launches in Berlin at ISMICS Annual Meeting

ATLANTA, June 15, 2010 - CorMatrix(R) Cardiovascular, a medical device company dedicated to
developing and delivering unique extracellular matrix (ECM) biomaterial
devices that harness the body's innate ability to repair damaged
cardiovascular tissue, announced today it has received CE mark for its
CorMatrix ECM for Cardiac Tissue Repair. With this designation, CorMatrix is
now able to market this product in European Union countries.

"This CE mark will allow surgeons in Europe to expand their use of
CorMatrix ECM to patients needing cardiac tissue repair," said Beecher Lewis,
President and Chief Operating Officer, CorMatrix. "We believe this additional
indication will allow us to significantly expand our presence outside of the
United States and drive growth in key markets."

CorMatrix's ECM for Cardiac Tissue Repair is used to repair heart
structures during open heart surgery - such as closing a hole in the heart
(known as atrial septal defect or ASD). During surgery, CorMatrix ECM is
sutured onto the heart tissue in need of repair. It then serves as a
scaffold, enabling the body's own cells to infiltrate and ultimately replace
and remodel the implanted ECM with native tissue. The anatomy is restored
naturally through the course of the body's innate wound healing process. It
works differently than other available surgical materials, as CorMatrix ECM
allows for repair of damaged tissue without leaving permanent synthetic or
foreign materials in the body, which can result in unwanted effects.

"Through my experience using CorMatrix ECM for pericardial closure
procedures, we've seen that it supports native tissue repair and provides
favorable outcomes for patients," said Prof. Giovanni Stellin, Chief
pediatric cardiac surgeon at the University of Padova. "The cardiac tissue
repair product will be a welcome addition to our surgical protocol."

Surgeons attending the International Society for Minimally Invasive
Cardiovascular Surgery (ISMICS) meeting in Berlin, June 16-19, 2010, may hear
more about CorMatrix ECM by visiting booth #6293 or during two poster
presentations featuring CorMatrix ECM Technology on Thursday, June 17.

CorMatrix ECM Technology has been commercially available in the U.S.
since 2006 and has been implanted in nearly 20,000 cardiac surgery procedures
at more than 300 hospitals in the U.S.

About CorMatrix ECM Technology

CorMatrix Cardiovascular holds an exclusive license from Purdue
University to research, develop, manufacture and market naturally occurring
ECM products for cardiovascular applications. The company currently has U.S.
clearance and European approval with a CE Mark for its ECM Technology as an
implant for pericardial closure and for use in cardiac tissue repair.

About CorMatrix Cardiovascular, Inc.

CorMatrix Cardiovascular, a privately held company based in Atlanta,
Georgia, is dedicated to developing and delivering innovative cardiovascular
devices that harness the body's innate ability to remodel damaged tissue. For
more information, visit www.cormatrix.com.

Becky Soja of WCG, +1-415-946-1080, bsoja at wcgworld.com, for CorMatrix Cardiovascular, Inc.